PERSONALIZED THERAPY OF TYPE 2 DIABETES MELLITUS

0Citations
Citations of this article
1Readers
Mendeley users who have this article in their library.

Abstract

Currently, the contribution of genetic factors to the development of type 2 diabetes is becoming more obvious. Despite the available nine classes of hypoglycemic drugs, only 35–40 % of patients achieve an adequate glycemic control. One the reasons may be the genetic heterogeneity of diabetes mellitus. An increasing number of studies indicates that an individual set of gene polymorphisms can determine the therapeutic response to a particular drug and cause the development of undesirable effects. The article presents an overview of a new direction in the diagnosis and treatment of diabetes mellitus – personalized medicine. The pathogenetic mechanisms of the development of the disease, its heterogeneity and the difficulties of choosing the most effective hypoglycemic therapy are described. Data on the pharmacogenetic features of metformin are presented.

References Powered by Scopus

Twelve type 2 diabetes susceptibility loci identified through large-scale association analysis

1531Citations
N/AReaders
Get full text

Cellular and molecular mechanisms of metformin: An overview

1412Citations
N/AReaders
Get full text

Metformin-Mode of action and clinical implications for diabetes and cancer

1047Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Kiseleva, T. A., Valeeva, F. V., & Islamova, D. R. (2023). PERSONALIZED THERAPY OF TYPE 2 DIABETES MELLITUS. Permskij Medicinskij Zurnal. Eco-Vector LLC. https://doi.org/10.17816/pmj40573-79

Save time finding and organizing research with Mendeley

Sign up for free